RSV Vaccines Show Strong Protection for Older Adults and Infants in Major Review
Comprehensive analysis of 14 trials reveals RSV vaccines reduce respiratory illness by up to 77% in older adults and 74% in infants through maternal vaccination.
Summary
A comprehensive Cochrane review of 14 randomized trials involving over 114,000 participants found that RSV prefusion vaccines significantly reduce respiratory illness in older adults by 77% and acute respiratory illness by 67%. Maternal vaccination with RSV F protein-based vaccines protected infants, reducing severe respiratory illness by 74% and hospitalizations by 54%. The vaccines showed good safety profiles with no significant increase in serious adverse events across all age groups studied.
Detailed Summary
Respiratory syncytial virus (RSV) causes significant respiratory illness across all age groups, with particularly severe impacts on older adults and infants. This comprehensive Cochrane systematic review analyzed the efficacy and safety of RSV vaccines across different populations to inform public health strategies.
Researchers conducted a thorough analysis of 14 randomized controlled trials involving 114,327 participants. The studies examined various RSV vaccine types across five distinct populations: older adults, pregnant women (for infant protection), women of childbearing age, and infants/children. The review followed rigorous Cochrane methodology with comprehensive literature searches through April 2024.
The results demonstrate compelling evidence for RSV vaccine effectiveness in key populations. RSV prefusion vaccines showed remarkable efficacy in older adults, reducing RSV-associated lower respiratory tract illness by 77% and acute respiratory illness by 67% with high-certainty evidence. Maternal vaccination strategies proved highly effective for infant protection, with RSV F protein-based vaccines reducing medically attended severe lower respiratory tract illness by 74% and hospitalizations by 54% in infants.
Safety profiles across all studied populations were reassuring, with no significant increases in serious adverse events, mortality from RSV, or all-cause mortality compared to placebo groups. This finding is particularly important for public health implementation, as it suggests these vaccines can be safely administered to vulnerable populations including older adults and pregnant women.
The clinical implications are substantial for respiratory disease prevention. These findings support the integration of RSV vaccines into routine immunization programs for older adults and maternal vaccination strategies. However, evidence remains limited for other populations, with very low certainty regarding vaccine effects in women of childbearing age and live-attenuated vaccines in children, indicating areas requiring further research.
Key Findings
- RSV prefusion vaccines reduced respiratory illness by 77% in older adults
- Maternal vaccination cut severe infant RSV illness by 74% and hospitalizations by 54%
- No significant increase in serious adverse events across all age groups
- Evidence remains uncertain for vaccines in women of childbearing age and children
- Phase III trials consistently showed low risk of bias and robust methodology
Methodology
Comprehensive Cochrane systematic review of 14 randomized controlled trials involving 114,327 participants across five populations. Studies compared RSV vaccines to placebo, other vaccines, or monoclonal antibodies using rigorous inclusion criteria and bias assessment tools.
Study Limitations
Evidence quality varies significantly by population, with very low certainty for vaccines in women of childbearing age and live-attenuated vaccines in children. English-language publication restriction may have excluded relevant studies from other languages.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.